Ma Yanhong, Han Fei, Chen Liangliang, Wang Hongya, Han Haidongqing, Yu Binfeng, Xu Ying, Chen Jianghua
Kidney Disease Center, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Key Laboratory of Kidney Disease Prevention and Control Technology, 79 Qingchun Road, Hangzhou, Zhejiang Province, 310003, People's Republic of China.
BMC Nephrol. 2017 Dec 29;18(1):381. doi: 10.1186/s12882-017-0782-4.
High-dose methylprednisolone pulses were one of the main treatments for anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitides (AAV) but had obvious side effects. We aimed to know the impact on renal survival and identify the prognostic factors of this treatment in Chinese AAV patients with severe renal involvement.
One hundred and eleven AAV patients with an estimated glomerular filtration rate (eGFR) of 10ml/min/1.73 m or less at admission were included. The MP group (n = 57) received intravenous methylprednisolone 500 mg/d for 3 days, while the control group (n = 54) had not. The outcomes and adverse events between two groups were compared. Besides, predictors for dialysis independence and good response of intravenous methylprednisolone were analyzed using Cox regression analysis and ROC curves respectively.
Their median duration of follow-up was 31 (range 3 to 134) months. Eleven patients in MP group and 20 patients in control group were died (P = 0.056). Twenty-one patients (36.8%) in MP group and 29 patients (53.7%) in control group were on maintaining dialysis (P = 0.088). Twenty-one patients in MP group remained dialysis independent, more than those in control group (4 patients, P <0.01). Urine protein creatinine ratio (hazard ratio 1.730, 95% confidence interval 1.029 to 2.909, P = 0.039) and the treatment of intravenous methylprednisolone pulses (hazard ratio 0.362, 95% confidence interval 0.190 to 0.690, P = 0.002) were the independent risk factors for dialysis independence. Those patients with serum creatinine≥855μmol/L and urine protein ≥3.7g/24h at admission may have worse responses to intravenous methylprednisolone pulses (sensibility 56.7%, specificity 85.0%, PPV 100.0% and NPV57.1%).
Intravenous methylprednisolone pulses could improve the long-term outcome in term of dialysis independence and tend to decrease mortality for Chinese AAV patients with severe renal involvement.
大剂量甲泼尼龙冲击疗法是抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)的主要治疗方法之一,但有明显副作用。我们旨在了解其对肾脏生存的影响,并确定该治疗方法在中国重症肾脏受累的AAV患者中的预后因素。
纳入111例入院时估计肾小球滤过率(eGFR)为10ml/min/1.73㎡或更低的AAV患者。甲泼尼龙组(n = 57)接受静脉注射甲泼尼龙500mg/d,共3天,而对照组(n = 54)未接受该治疗。比较两组的结局和不良事件。此外,分别使用Cox回归分析和ROC曲线分析静脉注射甲泼尼龙实现透析独立和良好反应的预测因素。
他们的中位随访时间为31(范围3至134)个月。甲泼尼龙组11例患者和对照组20例患者死亡(P = 0.056)。甲泼尼龙组21例患者(36.8%)和对照组29例患者(53.7%)维持透析(P = 0.088)。甲泼尼龙组21例患者仍无需透析,多于对照组(4例,P <0.01)。尿蛋白肌酐比(风险比1.730,95%置信区间1.029至2.909,P = 0.039)和静脉注射甲泼尼龙冲击疗法(风险比0.362,95%置信区间0.190至0.690,P = 0.002)是透析独立的独立危险因素。入院时血清肌酐≥855μmol/L且尿蛋白≥3.7g/24h的患者对静脉注射甲泼尼龙冲击疗法的反应可能较差(敏感性56.7%,特异性85.0%,阳性预测值100.0%,阴性预测值57.1%)。
对于中国重症肾脏受累的AAV患者,静脉注射甲泼尼龙冲击疗法可改善透析独立方面的长期结局,并倾向于降低死亡率。